TRULI activates the transcriptional activator Yap via inhibition of large tumor suppressor kinases (LATS) 1/2 (IC50 = 0.2 nM, EC50 = 510 nM HEK293A cells).1 It induced the proliferation of murine neonatal cardiomyocytes and human Müller glia in retinal organoids. TRULI reduced tumorigenicity of human chronic myelogenous leukemia cells and increased sensitivity to imatinib treatment.2 It moderated cartilage degeneration in an osteoarthritis model via modulation of ZBTB20.3
* VAT and and shipping costs not included. Errors and price changes excepted
